|Solubility||Soluble in DMSO.|
|Declaration||Manufactured by SynKinase.|
|Other Product Data||
Target: HDAC1, 2, 4, 10 and HDAC11 | Kinase Group: N/A | Substrate: N/A
Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
|Use/Stability||Stable for at least 2 years after receipt when stored at -20°C.|
|Product Specification Sheet|
Quisinostat (JNJ-26481585) is a novel second-generation panHDAC inhibitor of HDAC1, 2, 4, 10 and 11. Its highest potency is against HDAC1 with an IC50 of 0.11nM. It has only modest potency against HDACs 2, 4, 10, and 11 (IC50 ranging from 0.33nM to 0.64nM). It has low activity against HDACs 3, 5, 8, and 9 and its lowest potency is against HDACs 6 and 7.
- JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity: J. Arts, et al.; Clin. Cancer Res. 15, 6841 (2009)
- Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585: T. Stuehmer, et al.; Br. J. Haematol. 149, 529 (2010)